Dolutegravir

Dolutegravir has been studied in 20 papers since 2017: 1 trial and 8 observational studies in people, 2 in animals, 2 in cells, 6 reviews; 14 in the past year. It is an approved medicine. The newest paper, Nov 18, 2026: “Longitudinal changes in the odds of metabolic syndrome among people living with HIV receiving dolutegravir-, tenofovir alafenamide-, or protease…”.

InterventionApproved 2013

20 papers study it7 more mention it16 findingsUpdated

PubChemChEBIMeSH

4 new papers in 30 daysSee all 27 papers on dolutegravir

At a glance

One human study links dolutegravir to lower type 2 diabetes risk, while reviews describe higher hypertension risk in people with HIV and induction of fibrosis in preclinical models.

16 findings in 12 papers from 2017 to 2026, 6 of them since April 2026

Independent labs found the same change in people. 9 independent labs in 6 countries; 133 trials, none about aging, 53 with no results posted.

“After adjusting for age, BMI, and duration on antiretroviral therapy, Dolutegravir Initiators (aIRR=0.4) and Dolutegravir Transitioners (aIRR=0.4) had a lower risk than Non-Dolutegravir Users.”
Exploring the Relationship Between Dolutegravir and Diabetes Using Routine Data of Patients on Anti-Retroviral Treatment in a High HIV Prevalence SettingMedical research archives2026doi:10.18103/mra.v14i2.7309

None of its findings points the other way.

Humans: replicated by independent labs. Cells and worms or flies: a single group. Mice: nothing yet.
  • 9 independent labs in 6 countries
  • 133 trials, none about aging, 53 with no results posted
  • Funders: Kaohsiung Medical University and others
  • 4 of 14 findings with company ties
  • 60 of 133 trials sponsored by its developers
  • Human trial1
  • Humans8
  • Animals1
  • Model organisms1
  • Cells2
  • In silico1

What did studies of dolutegravir find?

9

Studies of dolutegravir measured 9 outcomes, among them inflammation, mortality and soluble CD14.

Inflammation

downin human cells2

2 studies
  1. Dolutegravir decreases inflammation in HCAECs.

    “Dolutegravir reduced inflammation by decreasing NFκB activation and IL-6/IL-8/sICAM-1/sVCAM-1 secretion, as did maraviroc with a milder effect.”

    Cellsin HCAECscoronary artery endothelial cell

    HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells

    PloS one

  2. Dolutegravir decreases inflammation in endothelial cells from adult donors.

    “Dolutegravir decreased inflammation, by inhibiting the NFκB pathway, and senescence, by repressing the p21 pathway.”

    Cellsin endothelial cells from adult donorscoronary artery15 days

    Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence

    Antiviral therapy

More on Inflammation

Mortality

upin silico1

1 study
  1. Dolutegravir increases mortality in silico (Scenario 4 HTN-attributable CVD mortality following rollout) (from 73% to 85% in women and 61% to 70% in men).

    “Following DTG rollout, mortality rose from 73% to 85% in women and 61% to 70% in men by 2022”

    In silicoScenario 4 HTN-attributable CVD mortality following rolloutby 2022

    Projected burden of hypertension-associated cardiovascular disease in people living with HIV versus HIV-negative adults in Eswatini

    medRxiv : the preprint server for health sciencesPreprint

Soluble CD14

downin humans1

1 study
  1. Dolutegravir is linked with lower soluble CD14 in humans (duration of dolutegravir-based therapy).

    “Duration of dolutegravir based therapy correlated negatively with sCD14 levels.”

    Humansduration of dolutegravir-based therapyn = 70

    Differential associations of anti-cytomegalovirus antibodies and soluble CD14 levels with immunosenescence in people living with HIV on long term antiretroviral therapy

    Immunity & ageing : I & A

More on Soluble CD14

Kidney function

upin humans1

1 study
  1. Dolutegravir improves kidney function in PLWH.

    “highlighting the possible beneficial effects of dolutegravir-based ART on improving the kidney function in PLWH”

    Reviewin PLWH

    A systematic review assessing the potential use of cystatin c as a biomarker for kidney disease in people living with HIV on antiretroviral therapy

    Frontiers in medicine

Lifespan

downin worms1

1 study
  1. Dolutegravir shortens lifespan in worms.

    “DTG resulted in lifespan reduction, which is dependent on increased levels of reactive oxidative species (ROS) accumulation.”

    Model organisms

    Dolutegravir-induced growth and lifespan effects in Caenorhabditis elegans

    BMC pharmacology & toxicology

Egg-hatching

downin worms1

1 study
  1. Dolutegravir decreases egg-hatching in worms.

    “decreased egg-hatching but had no effect on egg-laying.”

    Model organisms

    Dolutegravir-induced growth and lifespan effects in Caenorhabditis elegans

    BMC pharmacology & toxicology

Body growth

upin worms1

1 study
  1. Dolutegravir increases body growth in worms (early stage of treatment).

    “DTG enhanced body growth at the early stage of treatment, but no change was detected for long-term treatment.”

    Model organismsearly stage of treatment

    Dolutegravir-induced growth and lifespan effects in Caenorhabditis elegans

    BMC pharmacology & toxicology

Insulin resistance

downin human cells1

1 study
  1. Dolutegravir decreases insulin resistance in HCAECs.

    “dolutegravir improved and atazanavir/r worsened insulin resistance while maraviroc had no effect.”

    Cellsin HCAECscoronary artery endothelial cell

    HIV antiretroviral drugs, dolutegravir, maraviroc and ritonavir-boosted atazanavir use different pathways to affect inflammation, senescence and insulin sensitivity in human coronary endothelial cells

    PloS one

More on Insulin resistance

Cellular senescence

downin human cells1

1 study
  1. Dolutegravir decreases cellular senescence in endothelial cells from adult donors.

    “Dolutegravir decreased inflammation, by inhibiting the NFκB pathway, and senescence, by repressing the p21 pathway.”

    Cellsin endothelial cells from adult donorscoronary artery15 days

    Impact of CCR5, integrase and protease inhibitors on human endothelial cell function, stress, inflammation and senescence

    Antiviral therapy

More on Cellular senescence

What is dolutegravir linked with?

4

Studies link dolutegravir with 4 measures, among them hypertension, metabolic syndrome and incident hypertension.

Hypertension

upin humans2

2 studies
  1. Dolutegravir raises the risk of hypertension in people with HIV (doubles the risk).

    “dolutegravir exposure doubles the risk of incident hypertension even after adjustment for BMI change”

    Reviewin people with HIV

    Weight gain in people with HIV in Africa and Asia: a review of causes, consequences, and management implications

    Current opinion in HIV and AIDS

  2. Dolutegravir is associated with hypertension in humans among South African adult PLHIV receiving DTG-based ART.

    “Increased HPT risk after switching to DTG and rising blood pressure after ART initiation were associated with weight gain and older age.”

    Reviewamong South African adult PLHIV receiving DTG-based ART

    Hypertension among South African Adults Living with HIV Receiving Dolutegravir-Based Antiretroviral Therapy: A Scoping Review

    Afro-Egyptian Journal of Infectious and Endemic Diseases

More on Hypertension

Metabolic syndrome

upin humans2

2 studies
  1. Dolutegravir is linked with a higher risk of metabolic syndrome in adults living with HIV receiving ART (IRR 1.50, 95% CI 1.01, 2.23).

    “DTG-based regimen use (IRR 1.50; 95%CI 1.01, 2.23)”

    Humansin adults living with HIV receiving ARTmedian 43 monthsn = 325

    Metabolic syndrome and its risk factors among adults living with HIV receiving antiretroviral therapy in Zambia: an ambidirectional cohort study

    Scientific reports

  2. Dolutegravir is associated with metabolic syndrome in two Zambian studies of PLHIV.

    “integrase inhibitor-based regimens (particularly dolutegravir) were associated with increased MetS risk”

    Reviewin two Zambian studies of PLHIV

    Cardiometabolic Disease in Aging HIV-Positive Populations in Sub-Saharan Africa: A Scoping Review of Long-Term Antiretroviral Therapy Effects

    Research SquarePreprint

More on Metabolic syndrome

Incident hypertension

upin humans1

1 study
  1. Dolutegravir is associated with incident hypertension in humans (ART-naïve people with HIV in the INSTI subgroup; compared with EVG/c/FTC/TAF) (>2-fold adjusted hazard versus EVG/c/FTC/TAF; 5-year cumulative hypertension 37% versus 9%).

    “dolutegravir-based regimens carried a > 2-fold adjusted hazard versus EVG/c/FTC/TAF.”

    HumansART-naïve people with HIV in the INSTI subgroup; compared with EVG/c/FTC/TAFdolutegravir-based regimensn = 437

    First-line Antiretroviral Regimens and Risk of Incident Hypertension in People With HIV: a 15-year Cohort Study

    Open forum infectious diseases

More on Incident hypertension

Type 2 diabetes

downin humans1

1 study
  1. Dolutegravir is linked with a lower risk of type 2 diabetes in humans (aIRR=0.4).

    “After adjusting for age, BMI, and duration on antiretroviral therapy, Dolutegravir Initiators (aIRR=0.4) and Dolutegravir Transitioners (aIRR=0.4) had a lower risk than Non-Dolutegravir Users.”

    Humansafter adjusting for age, BMI, and duration on antiretroviral therapy, vs non-dolutegravir users

    Exploring the Relationship Between Dolutegravir and Diabetes Using Routine Data of Patients on Anti-Retroviral Treatment in a High HIV Prevalence Setting

    Medical research archives

More on Type 2 diabetes

Has dolutegravir been tested in people?

0 of 133 about aging

Yes: 1 trial and 8 observational studies in people have been published, and 133 trials are registered.

Latest change Latent tuberculosis: Phase 1 → Phase 1/2Oct 19, 2026

Approved

Repurposing

All 22

In trials

  • HIV 1

    Phase 4Completed2 trials

  • Body weight changes

    Phase 4Completed1 trial

  • Pregnancy related

    Phase 3Completed1 trial

  • Gram positive bacterial infection

    Phase 1/2Results posted1 trial

  • Virus disease

    Phase 1Results posted1 trial

  • Medication adherence

    Early phase 1Completed1 trial

Stopped

  • NCT02659761TerminatedAIDS

    Sponsor decision due to slow recruitment rates and no future recruitment foreseen

  • NCT02924389TerminatedHIV

    This study terminated early due to the ongoing covid-19 pandemic making it unsafe to recruit participants for in-person visits. Participants are living with HIV who are antiretroviral therapy-naive and are at high risk of COVID-19 complications.

  • NCT05193994TerminatedAmyotrophic lateral sclerosis

    A planned interim analysis resulted in the recommendation that the trial be stopped. The results showed no benefit of Triumeq for people with ALS compared with placebo on survival, the primary outcome measure.

  • NCT06658977TerminatedAmyotrophic lateral sclerosis

    This is a rollover study following the Lighthouse II trial; it was scheduled to stop when the LH II trial was stopped/completed. The LH II trial has been prematurely terminated so, likewise, this study has also now been stopped.

Who is developing dolutegravir?

3 companies: ViiV Healthcare, Merck Sharp & Dohme and Humanis Saglık Anonim Sirketi.

Companies
  • ViiV HealthcarePhase 3HIV infection, human immunodeficiency virus infection
  • Merck Sharp & DohmePhase 1
  • Humanis Saglık Anonim SirketiPhase 1HIV infection

Trial sponsors

Funding

2 grants since 2020

Fogarty International Center$345KEuropean Commission€5.2M

Latest

Dec 2025: 0Jan 2026: 1Feb 2026: 2Mar 2026: 1Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 2Aug 2026: 0Sep 2026: 3Oct 2026: 6Nov 2026: 118 papers in 12 months
Journal of Immunology

Immune gene variants linked to virus control in aged macaques

In an infection experiment, rhesus macaques aged 17–23 with protective immune gene variants had lower blood virus levels through 70 days than those without.In an infection experiment, rhesus macaques aged 17–23 with protective immune gene variants had lower blood virus levels through 70 days than those without.

Animal study · 16 animalsBlood and immune system

See all 27 papers on dolutegravir